Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals.
| Brand name | VENLAFAXINE HYDROCHLORIDE |
| Generic name | VENLAFAXINE HYDROCHLORIDE |
| Active ingredient(s) | VENLAFAXINE HYDROCHLORIDE |
| Distributed by / for | Zydus Pharmaceuticals (USA) Inc |
| NDC | 68382-034-16 |
| Full product label | Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles (NDC 68382-034-16) and b)1000-count bottles (NDC 68382-034-10), Rx only, Mfg. by: Zydus Lifesciences Ltd. Ahmedabad, India; Dist. by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Distribution | Nationwide within the United States |
| Quantity | a) 13,128 bottles; b) 252 bottles |
| Recall initiated | 2024-06-21 |
| Report date | 2024-07-31 |
| Recall completed | 2025-08-06 |
| Recall number | D-0617-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Pennington NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗